

Francesco Amati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9851119/publications.pdf>

Version: 2024-02-01

43
papers

420
citations

840585

11
h-index

794469

19
g-index

44
all docs

44
docs citations

44
times ranked

580
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophil elastase in bronchiectasis. <i>Respiratory Research</i> , 2017, 18, 211.	1.4	75
2	The biology of pulmonary exacerbations in bronchiectasis. <i>European Respiratory Review</i> , 2019, 28, 190055.	3.0	48
3	Prognostic parameters of in-hospital mortality in COVID-19 patients: An Italian experience. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13629.	1.7	31
4	SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. <i>Respiratory Medicine</i> , 2021, 180, 106355.	1.3	25
5	Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 111-114.	0.3	25
6	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. <i>Chest</i> , 2021, 159, 58-72.	0.4	24
7	T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis. <i>Biomedicines</i> , 2021, 9, 772.	1.4	24
8	COVID-19 multidisciplinary high dependency unit: the Milan model. <i>Respiratory Research</i> , 2020, 21, 260.	1.4	22
9	COVID-19 in lung transplant recipients: A case series from Milan, Italy. <i>Transplant Infectious Disease</i> , 2020, 22, e13356.	0.7	19
10	Protease-Antiprotease Imbalance in Bronchiectasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5996.	1.8	17
11	Comparison of different conditions for DNA extraction in sputum - a pilot study. <i>Multidisciplinary Respiratory Medicine</i> , 2019, 14, 6.	0.6	14
12	Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 977.	1.8	14
13	Predictors of Helmet CPAP Failure in COVID-19 Pneumonia: A Prospective, Multicenter, and Observational Cohort Study. <i>Canadian Respiratory Journal</i> , 2022, 2022, 1-6.	0.8	11
14	Investigating the Etiology of Bronchiectasis: You Do Not Find What You Do Not Look For. <i>Respiration</i> , 2017, 93, 228-229.	1.2	10
15	COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemic. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1576-1578.	2.8	10
16	Lung Recruitability of COVID-19 Pneumonia in Patients Undergoing Helmet CPAP. <i>Archivos De Bronconeumología</i> , 2021, 57, 92-94.	0.4	10
17	When and how ruling out cystic fibrosis in adult patients with bronchiectasis. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 29.	0.6	8
18	COVID-19 in Immunocompromised Patients: A Systematic Review. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 839-858.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Emerging Resistance of Gram Negative Pathogens in Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 480-495.	0.8	6
20	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	1.5	6
21	Diagnosis and Initial Investigation of Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 513-524.	0.8	4
22	Post-COVID-19 sequelae. , 2021, , 180-196.		4
23	Site of care and multidisciplinary approach. , 0, , 353-370.		2
24	An extensive bundle of tests is needed to detect treatable causes of bronchiectasis (Bx). , 2018, , .		1
25	What is the best technique to extract bacterial DNA from sputum?. , 2018, , .		1
26	Cardiovascular side-effects of common antibiotics. , 2020, , 264-278.		1
27	P104 Prevalence, clinical characteristics and outcomes of patients referred to an adult cystic fibrosis centre from pulmonary clinics. Journal of Cystic Fibrosis, 2018, 17, S88-S89.	0.3	0
28	2019 ATS/IDSA CRITERIA TO IDENTIFY P. AERUGINOSA AND MRSA PROMOTE OVERUTILIZATION OF MRSA THERAPY IN NON-SEVERE CAP. Chest, 2020, 157, A91.	0.4	0
29	YOU DONâ€™T FIND WHAT YOU DONâ€™T LOOK FOR: PREVALENCE OF IMMUNODEFICIENCY IN PATIENTS WITH CYSTIC FIBROSIS USING A BROAD IMMUNOLOGICAL SCREENING. Chest, 2020, 157, A90.	0.4	0
30	Phenotyping in bronchiectasis: Are we moving toward a personalized medicine?. Community Acquired Infection, 2016, 3, 96.	0.1	0
31	Sputum glucose as a marker of disease severity in adult patients with cystic fibrosis. , 2018, , .		0
32	Validation of the Italian version of Bronchiectasis Quality of Life Questionnaire (QoL-B). , 2018, , .		0
33	Clinical characteristics and disease severity of adults with cystic fibrosis with at least one residual function mutation. , 2018, , .		0
34	Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE). , 2018, , .		0
35	Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation. , 2018, , .		0
36	Comparison of different conditions for DNA extraction in sputum - a pilot study. Multidisciplinary Respiratory Medicine, 0, 14, .	0.6	0

#	ARTICLE	IF	CITATIONS
37	Prevalence of <i>S. pneumoniae</i> colonization and serotypes in sputum of vaccine-naive adults with cystic fibrosis. , 2019, , .		0
38	<i>S. pneumoniae</i> prevalence and serotypes in sputum of stable bronchiectasis. , 2019, , .		0
39	Respiratory viruses in adults with cystic fibrosis during stable and exacerbations. , 2019, , .		0
40	When and how ruling out cystic fibrosis in adult patients with bronchiectasis. Multidisciplinary Respiratory Medicine, 0, , .	0.6	0
41	Novel <i>Pseudomonas aeruginosa</i> scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumonia. , 2020, , .		0
42	Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia. , 2020, , .		0
43	Respiratory failure in COVID-19: a patient's perspective and clinical cases. , 2021, , 1-13.		0